PerkinElmer launches new assay kits to support biotherapeutic drug development

PerkinElmer has added a range of new assay kits to its product portfolio.

PerkinElmer has launched a new range of assay kits designed to help improve the safety testing, manufacturing and quality control of biotherapeutics.

The new kits utilise the company's AlphaLISA technology, which enables higher quality results than the alternative ELISA technology in half the time.

AlphaLISA technology can therefore help to speed up the drug discovery process, as well as producing greater precision thanks to having fewer assay steps than standard ELISA.

The new assays were also designed with regulators' stringent performance requirements in relation to drug impurities and toxic effects in mind.

Kevin Hrusovsky, president of life sciences and technology at PerkinElmer, said that the company "is continuously seeking new ways to improve human health through the development of innovative technologies".
"Adverse reactions due to drug toxicity is a real issue that we are passionate about helping to minimise," he explained.

Mr Hrusovsky added that the company is "excited" that its new assay kits will enable its customers to improve the safety and efficiacy of new biotherapeutic drugs being developed.